Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding)

American Journal of Cardiology

Volumn 111, Issue 8, 2013, Pages 1159-1164

  Roldán, Vanessa ^a   Marín, Francisco ^b   Fernández, Hermógenes ^a   Manzano Fernández, Sergio ^b   Gallego, Pilar ^a   Valdés, Mariano ^b   Vicente, Vicente ^a   Lip, Gregory Y H ^c  

^a HOSPITAL MORALES MESEGUER   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LOGISTIC MODELS; MALE; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY; RISK FACTORS; STATISTICS, NONPARAMETRIC; THROMBOEMBOLISM;

EID: 84875850514     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.12.045     Document Type: Article

References (30)

1. V. Roldán, F. Marín, B. Muiña, J.M. Torregrosa, D. Hernández-Romero, M. Valdés, V. Vicente, and G.Y. Lip Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients J Am Coll Cardiol 57 2011 2496 2504
2. P. Gallego, V. Roldán, J.M. Torregrosa, J. Gálvez, M. Valdés, V. Vicente, F. Marín, and G.Y. Lip Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events and mortality in anticoagulated patients with atrial fibrillation Circ Arrhythm Electrophysiol 5 2012 312 318
3. A.J. Camm, G.Y. Lip, R. De Caterina, I. Savelieva, D. Atar, S.H. Hohnloser, G. Hindricks, P. Kirchhof ESC Committee for Practice Guidelines 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
4. S. Schulman, C. Kearon, and Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
5. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
6. A.S. Levey, J. Coresh, T. Greene, L.A. Stevens, Y.L. Zhang, S. Hendriksen, J.W. Kusek, F. Van Lente Chronic Kidney Disease Epidemiology Collaboration Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate Ann Intern Med 145 2006 247 254
7. National Kidney Foundation K/DOQI clinical practice guidelines form chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 S266
8. A.S. Go, M.C. Fang, N. Udaltsova, Y. Chang, N.K. Pomernacki, L. Borowsky, D.E. Singer ATRIA Study Investigators Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Circulation 119 2009 1363 1369
9. J. Kooiman, W.R. van de Peppel, F.J. van der Meer, and M.V. Huisman Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs J Thromb Haemost 9 2011 1652 1653
10. A. Alonso, F.L. Lopez, K. Matsushita, L.R. Loehr, S.K. Agarwal, L.Y. Chen, E.Z. Soliman, B.C. Astor, and J. Coresh Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk In Communities (ARIC) study Circulation 123 2011 2946 2953
11. K.M. Jönsson, M. Wieloch, G. Sterner, U. Nyman, S. Elmståhl, G. Engström, and P.J. Svensson Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden Thromb Res 128 2011 341 345
12. K. Nakagawa, T. Hirai, S. Takashima, N. Fukuda, K. Ohara, E. Sasahara, Y. Taguchi, N. Dougu, T. Nozawa, K. Tanaka, and H. Inoue Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation Am J Cardiol 107 2011 912 916
13. H. Fujii, J.I. Kim, K. Yoshiya, S. Nishi, and M. Fukagawa Clinical characteristics and cardiovascular outcomes of hemodialysis patients with atrial fibrillation: a prospective follow-up study Am J Nephrol 34 2011 126 134
14. R. Marinigh, D.A. Lane, and G.Y. Lip Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk J Am Coll Cardiol 57 2011 1339 1348
15. A.H. Abdelhafiz, M.P. Myint, J.A. Tayek, and N.M. Wheeldon Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis Clin Ther 31 2009 1534 1539
16. J.P. Dimarco, G. Flaker, A.L. Waldo, S.D. Corley, H.L. Greene, R.E. Safford, L.E. Rosenfeld, G. Mitrani, M. Nemeth AFFIRM Investigators Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study Am Heart J 149 2005 650 656
17. S. Manzano-Fernández, F. Cambronero, C. Caro-Martínez, J.A. Hurtado-Martínez, F. Marín, F.J. Pastor-Pérez, A. Mateo-Martínez, M. Sánchez-Martínez, E. Pinar-Bermúdez, and M. Valdés Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting Thromb Haemost 107 2012 51 58
18. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey Chest 138 2010 1093 1100
19. R.J. Beyth, L.M. Quinn, and C.S. Landefeld Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin Am J Med 105 1998 91 99
20. B.F. Gage, Y. Yan, P.E. Milligan, A.D. Waterman, R. Culverhouse, M.W. Rich, and M.J. Radford Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J 151 2006 713 719
21. M.C. Fang, A.S. Go, Y. Chang, L.H. Borowsky, N.K. Pomernacki, N. Udaltsova, and D.E. Singer A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study J Am Coll Cardiol 58 2011 395 401
22. J.B. Olesen, G.Y. Lip, A.L. Kamper, K. Hommel, L. Køber, D.A. Lane, J. Lindhardsen, G.H. Gislason, and C. Torp-Pedersen Stroke and bleeding in atrial fibrillation with chronic kidney disease N Engl J Med 367 2012 625 635
23. F. Yang, D. Chou, P. Schweitzer, and S. Hanon Warfarin in haemodialysis patients with atrial fibrillation: what benefit? Europace 12 2010 1666 1672
24. S.H. Hohnloser, and S.J. Connolly Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope Eur Heart J 32 2011 2347 2349
25. V. Pengo, L. Crippa, A. Falanga, G. Finazzi, F. Marongiu, G. Palareti, D. Poli, S. Testa, E. Tiraferri, A. Tosetto, A. Tripodi, C. Manotti Italian Federation of Thrombosis Centers Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation: a consensus document of the Italian Federation of Thrombosis Centers (FCSA) Thromb Haemost 106 2011 868 876
26. B.K. Poulsen, E.L. Grove, and S.E. Husted New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function Drugs 72 2012 1739 1753
27. K.E. Chan, J.M. Lazarus, R. Thadhani, and R.M. Hakim Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation J Am Soc Nephrol 20 2009 2223 2233
28. N.A. Limdi, T.M. Beasley, M.F. Baird, J.A. Goldstein, G. McGwin, D.K. Arnett, R.T. Acton, and M. Allon Kidney function influences warfarin responsiveness and hemorrhagic complications J Am Soc Nephrol 20 2009 912 921
29. G. Palareti, and B. Cosmi Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients Thromb Haemost 102 2009 268 278
30. G. Cam, A.T. Kwetcheu, C. Vigneau, P. Siohan, G. Queffeulou, P. Gatault, E. Laruelle, A. Crémault, P. Le Cacheux, N. Rioux-Leclercq, and E. Renaudineau Acute and chronic nephropathy induced by fluindione must be addressed Nephrol Dial Transplant 27 2012 1554 1558